MelaFind® Featured On "The Rachael Ray Show"

                 MelaFind® Featured On "The Rachael Ray Show"

PR Newswire

IRVINGTON, N.Y., Oct. 15, 2013

IRVINGTON, N.Y., Oct. 15, 2013 /PRNewswire/ --MELA Sciences, Inc. (NASDAQ:
MELA), the medical device company that has developed and is commercializing
MelaFind®, the first and only FDA approved optical diagnostic device for
melanoma detection used by dermatologists in their fight against melanoma,
today announced that MelaFind® was featured on "The Rachael Ray Show," the
Emmy award-winning national daytime talk show hosted by celebrity chef and
best-selling author Rachael Ray.


The "Future of Medicine" segment aired on October 9, 2013 and reported on the
latest advancements in medicine and technology. Board-certified dermatologist
Dr. Cheryl M. Burgess highlighted MelaFind® as a breakthrough device in the
detection of melanoma, the fastest growing cancer in the country. MelaFind®
helps dermatologists identify melanoma at its most treatable stage by
providing more information and data up to 2.5 mm below the skin's surface
during melanoma skin examinations. This is the first time dermatologists have
an FDA approved objective technology to help them establish a management plan
for ambiguous moles.

The MelaFind® portion of the segment reinforced the importance of skin cancer
exams, early melanoma detection and how new technologies, like MelaFind®, are
helping in the process. Rachael Ray also noted that skin cancer exams should
be a priority, stating that "unless people have a family history of melanoma,
they don't understand how serious it is or how deadly it can be." If caught
early, melanoma is almost 100% curable.

Dr. Burgess demonstrated MelaFind® on an audience member's ambiguous mole,
taking viewers through a step-by-step process of a MelaFind® exam, explaining
how dermatologists analyze results and ultimately determine the best course of
action for a patient. She explained how MelaFind® acts as a "mini MRI" to
analyze the mole, allowing dermatologists to study the results and ultimately
determine the best course of action for a patient.

Click here to see more details on the "Future of Medicine" segment from the
"The Rachael Ray Show."

MELA Sciences, Inc.'s Interim Chief Executive Officer Robert Coradini said,
"We are honored that MelaFind® was one of the medical breakthroughs
highlighted on 'The Rachael Ray Show.' Knowing that melanoma is a nationwide
epidemic, our goal is to provide dermatologists with MelaFind® as a tool to
aid in the diagnosis of this disease. We thank Rachael Ray for bringing
attention to the issue of melanoma, and also thank Dr. Cheryl Burgess for
spreading the news about MelaFind® and being a longtime advocate and user of
the device."

According to the skin cancer foundation, of the seven most common cancers in
the U.S., melanoma is the only cancer with an increasing incidence. Melanoma
is almost 100% curable if caught early, but according to a Harris Interactive
Study commissioned by MELA Sciences, Inc., only 24 percent of American adults
have had a skin check by a dermatologist, which can lead to missed cases as
well as potentially advanced and fatal stages.

MelaFind® has been recognized by the Cleveland Clinic as a Top 10 Medical
Innovation for 2013 and was recently featured in The Wall Street Journal.
Consumers can learn more about the device or locate a dermatologist with
MelaFind® in their area by visiting

About MELA Sciences, Inc.
MELA Sciences, Inc. is a medical device company focused on the
commercialization of its flagship product, MelaFind® ^ and its further design
and development.MelaFind® is a non-invasive tool that provides additional
information to dermatologists during melanoma skin examinations. The device
uses light from visible to near-infrared wavelengths to evaluate skin lesions
up to 2.5 mm beneath the skin. The device supplies information on a lesion's
level of morphologic disorganization to provide additional objective
information that may be used by dermatologists in the biopsy decision-making
process. MelaFind® has been approved by the U.S. Food and Drug Administration
for use in the U.S. In addition, MelaFind® has received CE Mark approval and
is approved for use in the European Union.

For more information on MELA Sciences, Inc., visit

Safe Harbor:
This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes," "assumes," "predicts" and
variations of such words or similar expressions that predict or indicate
future events or trends, or that do not relate to historical matters. These
statements are based on our current beliefs or expectations and are inherently
subject to significant known and unknown uncertainties and changes in
circumstances, many of which are beyond our control. There can be no assurance
that our beliefs or expectations will be achieved. Actual results may differ
materially from our beliefs or expectations due to financial, economic,
business, competitive, market, regulatory and political factors or conditions
affecting the company and the medical device industry in general, as well as
more specific risks and uncertainties facing the company such as those set
forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and
Exchange Commission (the "SEC"). Factors that might cause such a difference
include whether MelaFind® achieves market acceptance. Given the uncertainties
affecting companies in the medical device industry such as the Company, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements. The
Company urges you to carefully review and consider the disclosures found in
its filings with the SEC which are available at and

SOURCE MELA Sciences, Inc.

Contact: Investors, Lynn Pieper, Westwicke Partners, 415-202-5678; Media, Asia
Young, Rpr Marketing Communications, 212-317-1462,
Press spacebar to pause and continue. Press esc to stop.